How did Biogen’s mid-stage Alzheimer’s trial results compare to approved drugs?

Biogen’s experimental Alzheimer’s drug slowed cognitive decline at a rate similar to currently approved treatments, according to mid-stage trial data. The company has not released detailed results or regulatory plans, and its SEC filings suggest the readout was not considered a major corporate event.